Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $42.19, for a total value of $632,850.00. Following the sale, the chief executive officer directly owned 642,540 shares of the company’s stock, valued at $27,108,762.60. The trade was a 2.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Cameron Turtle also recently made the following trade(s):

• On Monday, February 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $32.80, for a total transaction of $492,000.00.
• On Friday, January 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $30.68, for a total value of $460,200.00.

Spyre Therapeutics Stock Performance

Shares of NASDAQ SYRE traded down $2.42 during trading on Tuesday, reaching $40.07. The company had a trading volume of 921,701 shares, compared to its average volume of 747,590. The business’s 50 day moving average price is $34.73 and its 200-day moving average price is $26.74. The stock has a market cap of $3.15 billion, a PE ratio of -19.26 and a beta of 3.09. Spyre Therapeutics, Inc. has a 52 week low of $10.91 and a 52 week high of $45.76.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Thursday, February 26th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.04). Equities analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. BTIG Research reiterated a “buy” rating and set a $70.00 target price on shares of Spyre Therapeutics in a research report on Friday, February 20th. Leerink Partners upgraded Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, February 19th. Mizuho raised Spyre Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company boosted their target price on Spyre Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $53.44.

Institutional Trading of Spyre Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SYRE. CWM LLC boosted its position in Spyre Therapeutics by 357.8% in the second quarter. CWM LLC now owns 1,712 shares of the company’s stock valued at $26,000 after buying an additional 1,338 shares during the last quarter. AlphaQuest LLC lifted its position in shares of Spyre Therapeutics by 30.8% during the 2nd quarter. AlphaQuest LLC now owns 4,174 shares of the company’s stock worth $62,000 after buying an additional 983 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Spyre Therapeutics by 2,881.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after purchasing an additional 4,092 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Spyre Therapeutics during the 4th quarter worth $74,000. Finally, Ameritas Investment Partners Inc. grew its stake in Spyre Therapeutics by 25.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,091 shares of the company’s stock valued at $76,000 after acquiring an additional 1,045 shares during the last quarter. 80.39% of the stock is currently owned by institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.